Woo Raymond sold $35K of CBLL

Woo Raymond (Chief Technology Officer) sold 1,966 shares of Ceribell, Inc. (CBLL) at $18.00 on 2026-05-21.

Original reporting
SEC EDGAR · Woo Raymond
Published May 26, 2026, 8:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 26, 2026, 8:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CBLL
Bearish
low confidence
Mentioned
$CBLL
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CBLLBearishLow
01

Why it matters

The only actionable item is an officer’s open-market sale; there are no accompanying operational or corporate events that would change valuation fundamentals.

02

Market read

Traders may briefly reassess sentiment around CBLL due to officer selling, but the disclosure alone is unlikely to materially move the stock.

03

What to watch

No 10b5-1 plan is cited, but Form 4s can reflect tax/financial planning; without a pattern across multiple filings, directional inference is unreliable.

Relevance 6/10Timing: Immediate for monitoring/positioning; unlikely to drive a sustained repricing without additional news.

Background

The article is a SEC Form 4 insider transaction disclosure for Ceribell, Inc. (CBLL).

Company-level read

Ticker impact

$CBLLBearishLow confidence
Context

Ceribell CTO Woo Raymond filed an open-market sale of 1,966 shares at $18.00 on 2026-05-21 (Form 4).

Expected impact

Likely limited near-term impact; any reaction should be muted unless follow-on selling accelerates.

Evidence & confidence

The filing is an insider transaction without disclosed fundamental catalysts (no earnings/M&A/trial). Share count and dollar value are relatively small, and lack of a stated 10b5-1 plan increases interpretive noise rather than providing a clear directional catalyst.

Market effects

Minimal; insider Form 4 selling typically does not reset sector fundamentals.

None indicated; this is company-specific insider activity.

None indicated; no cross-border deal/regulatory catalyst mentioned.

Counterpoint

The sale could be routine liquidity/portfolio management and may not reflect company outlook, especially with holdings still substantial post-sale.

Key entities

  • Ceribell, Inc.

    CBLL insider transaction: CTO Woo Raymond sold 1,966 shares at $18.00 on 2026-05-21.

  • Woo Raymond

    Chief Technology Officer who reported the sale; holdings after transaction: 195,682 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CBLLMedAI 8/10

CeriBell Inc (CBLL) (Q3 2026) Earnings Call Highlights: Record Hospital Additions

CeriBell Inc (CBLL) reported Q3 2026 revenue of $29.3M, up 30% YoY, with 35 new hospitals added. Gross margin improved to 90%, but net loss widened to $21.4M. Full-year guidance raised to $115-$117M. Delirium monitoring pilot showed clinical impact, but no material revenue contribution yet. Operating expenses rose 36% YoY. CEO Jane Chao and CFO Scott Blomberg discussed growth strategies and 2027 outlook.

$CBLLHigh

Ceribell Reports Third Quarter 2026 Financial Results

Ceribell, Inc. (CBLL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Ceribell Reports Third Quarter 2026 Financial Results Sunnyvale, Calif. – November 3, 2026 – CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today repor

$EWHighAI 8/10

Weekly Buzz: EW, ABBV, MIRM Score FDA Wins, AZN, NVO Strike Deals; LLY, KOD Report Data

Edwards Lifesciences (EW) received FDA approval for a pediatric heart valve. Ceribell (CBLL) and SI-BONE (SIBN) cleared new software and spinal fusion systems. Teva (TEVA) added a biosimilar to its portfolio. AbbVie (ABBV) and Mirum (MIRM) gained FDA approvals for Parkinson's and rare disease treatments. Merck (MRK) withdrew a lung cancer drug filing. Sanofi (SNY) and Regeneron (REGN) expanded their immunology alliance.

$CBLLMedAI 8/10

Ceribell Receives FDA 510(k) Clearance for Quantitative EEG Trending and Amplitude-Integrated EEG Analysis

Ceribell, Inc. (Nasdaq: CBLL) received FDA 510(k) clearance for new software for its EEG system, enabling easier interpretation of brain activity trends. The update includes Alpha-Delta Ratio, Burst Suppression, and Amplitude-Integrated EEG monitoring, applicable to patients of all ages. The company expects to roll out the features in the first half of 2027.